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Background: It has been well documented that pre-eclampsia and unexplained fetal growth restriction (FGR) have
a common etiological background, but little is known about their linkage at the molecular level. The aim of this
study was to further investigate the mechanisms underlying pre-eclampsia and unexplained FGR.
Methods: We analyzed differentially expressed genes in placental tissue from severe pre-eclamptic pregnancies
(n = 8) and normotensive pregnancies with or (n = 8) without FGR (n = 8) using a microarray method.
Results: A subset of the FGR samples showed a high correlation coefficient overall in the microarray data from the
pre-eclampsia samples. Many genes that are known to be up-regulated in pre-eclampsia are also up-regulated in
FGR, including the anti-angiogenic factors, FLT1 and ENG, believed to be associated with the onset of maternal
symptoms of pre-eclampsia. A total of 62 genes were found to be differentially expressed in both disorders.
However, gene set enrichment analysis for these differentially expressed genes further revealed higher expression
of TP53-downstream genes in pre-eclampsia compared with FGR. TP53-downstream apoptosis-related genes, such
as BCL6 and BAX, were found to be significantly more up-regulated in pre-eclampsia than in FGR, although the
caspases are expressed at equivalent levels.
Conclusions: Our current data indicate a common pathophysiology for FGR and pre-eclampsia, leading to an up-
regulation of placental anti-angiogenic factors. However, our findings also suggest that it may possibly be the
excretion of these factors into the maternal circulation through the TP53-mediated early-stage apoptosis of
trophoblasts that leads to the maternal symptoms of pre-eclampsia.
Background
Pre-eclampsia is one of the most common and poten-
tially serious pregnancy-associated disorders and is a
principal cause of maternal morbidity, accounting for
almost 15-20% of pregnancy-related mortalities [1]. Pre-
eclampsia is not a simple complication of pregnancy,
but is a syndrome involving multiple organ failure
including that of the liver, kidney, lung, and the coagula-
tory and neural systems. The prognosis for both the
mother and fetus in cases of severe pre-eclampsia is
poorer than generally expected, particularly in early
onset cases (<34 weeks of gestation) [2]. Although these
patients are generally treated for prevention of seizures
and control of hypertension, the lack of understanding
of the precise etiology of pre-eclampsia has hindered the
development of preventive and therapeutic measures to
treat this disease based on its etiology. Since the risks of
maternal multi-organ dysfunction and fetal distress are
higher in the early onset forms of this disorder, it has
been recommended that the fetus should be delivered
during gestational weeks 32-34 in such cases [1].
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sia is a complex polygenetic trait in which maternal and
fetal genes, as well as environmental factors, are
involved. However, the pathogenetic process involves
numerous factors such as oxidative stress, endothelial
dysfunction, vasoconstriction, metabolic changes, throm-
botic disorders and inflammatory responses, and the
precise underlying mechanisms have remained elusive
[3,4]. It has also been formally considered, however, that
the placenta plays a primary role in the etiology of this
disorder. In support of this idea is the observation that
patients with pre-eclampsia recover from clinical symp-
toms of the disorder just after the delivery of the fetus
and placenta, that pre-eclampsia occurs in patients with
a hydatidiform mole characterized by trophoblast hyper-
plasia in the absence of any tissues of fetal origin, and
also that paternity is a significant risk factor for pre-
eclampsia [5]. Several recent lines of evidence have also
indicated that placenta-derived anti-angiogenic factors,
such as soluble fms-like tyrosine kinase-1 and soluble
endoglin, significantly contribute to the onset of pre-
eclampsia [6,7].
Fetal growth restriction (FGR) is another clinical entity
that increases the risk of perinatal morbidity and mor-
tality and can result from heterogeneous causes, includ-
ing maternal, fetal and placental factors. FGR may result
from defects in endogenous developmental and growth
factors, whereas a placental defect may inhibit the trans-
port of nutrients and oxygen from mother to fetus [8].
Some forms of unexplained FGR have been etiologically
linked to pre-eclampsia since they show common patho-
logic features in the placenta, although this assertion has
remained controversial [9]. A failure of trophoblast inva-
sion leading to abnormal shallow vascularity and
impaired remodeling of the spiral arteries appears to be
a common process behind these disorders [10].
Although pre-eclamptic placentas generally manifest
fewer morphological changes than those of FGR cases,
the placentas from early-onset cases of pre-eclampsia
display substantial villous and vascular abnormalities
[11,12]. In this context, it could be hypothesized that a
subset of FGR and early-onset pre-eclampsia cases are
likely to share common etiologies, and that the presence
or absence of maternal risk factors determines disease
manifestation, but this contention remains speculative
[13].
Given the current evidence base, it is of clinical
importance to compare the gene expression profiles of
pre-eclampsia and FGR to further our understanding of
their respective etiologies and aid in the future develop-
ment of new therapies. In our current study, we have
performed such global gene expression profiling via oli-
gonucleotide microarrays of placental tissue from severe




All clinical samples were collected at the Department of
Obstetrics and Gynecology, Fujita Health University,
Japan. Informed consent was obtained from each patient
and the study protocol was approved by the Ethical
Review Board for Human Genome Studies at Fujita
Health University (Accession number 43 and 87,
approved on February 23, 2005 and March 24, 2010,
respectively). A total of 24 placental biopsies were
obtained from severe pre-eclamptic pregnancies (n =8 )
and normotensive pregnancies with (n = 8) or without
FGR (n = 8). Pre-eclampsia was defined as a blood pres-
sure of higher than 140/90 mmHg, with proteinuria of
more than 0.3g in a 24 hour collection. The pre-eclamp-
sia was considered severe if one or more of the follow-
ing criteria were present: a blood pressure of higher
than 160/110 mmHg, or proteinuria of more than 2g in
a 24 hour collection [14]. FGR was diagnosed when the
birth weight was below the 10th percentile of that
anticipated for the given gestational age for a Japanese
population [15]. Unexplained FGR was defined by the
exclusion of known maternal and fetal factors including
maternal systemic diseases, multiple gestation, fetal con-
genital infection, structural abnormalities and chromo-
somal abnormalities. Additionally, all FGR cases showed
clinical signs of disturbed placental function such as
asymmetric growth, oligohydroamnions, and/or
increased pulsatility index of the umbilical artery. Nor-
motensive subjects with or without FGR were matched
for maternal and gestational ages, and for body mass
index during pre-pregnancy (Table 1).
Placental biopsy collection
All of the placental biopsies, both from pre-eclamptic
and normotensive pregnancies with or without FGR,
were obtained following Caesarean sections. In normo-
tensive cases, Caesarean sections were performed due to
previous Caesarean sections. To avoid any effects of
labor upon the gene expression profiles of the tissue
samples, only placental samples that were obtained from
the women who had not undergone labor were included
in the study. A central area of chorionic tissue was dis-
sected, and the maternal deciduas and amnionic mem-
branes were removed. We then dissected 1 cm sections
of placental villi from the four different central areas
between the basal and chorionic plates. After vigorous
washing of the maternal blood with saline, tissues were
i m m e d i a t e l yf r o z e ni nl i q u i dn i t r o g e na n ds t o r e du n t i l
use.
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Total RNA was extracted from the chorionic villous tis-
sues with an RNeasy mini-kit (Qiagen Inc., Valencia,
CA) in accordance with the manufacturer’s instructions.
The quality of the RNA samples was determined by
electrophoresis through denaturing agarose gels and
staining with ethidium bromide. We measured the
intensities of 28S and 18S rRNAs and a higher than 2:1
ratio was considered the benchmark for intact RNA.
The RNA was quantified and evaluated for purity by UV
spectrophotometry. RNA samples obtained from four
different areas of a single placenta were mixed prior to
expression analyses. To further assess the quality of the
RNA, all specimens were subjected to expression analy-
sis of the housekeeping gene, glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), using conventional RT-
PCR. To test for possible contamination by maternal
blood, the expression of a leukocyte-specific gene (leu-
kocyte common antigen; LCA) was also examined using
conventional semi-quantitative RT-PCR [16].
Microarray analysis
Microarray experiments were performed using the Affy-
metrix GeneChip system (Affymetrix, Santa Clara, CA).
Briefly, approximately 1 μg of each total RNA sample was
used for double strand cDNA synthesis. cRNA was synthe-
sized by in vitro transcription followed by sense-strand
cDNA synthesis using the Ambion Whole Transcript
Expression Kit (Applied Biosystems, Foster City, CA).
After fragmentation into ~200 bp strands with uracil
DNA glycosylase, synthesized sense-strand cDNAs were
end-labeled with biotin, and then hybridized to an Affyme-
trix Human Exon 1.0 ST Array. Signal intensities were
amplified via secondary staining with a biotin-labeled anti-
streptavidin antibody followed by phycoerythrin-streptavi-
din staining. Fluorescent image arrays were obtained using
a GeneChip Scanner 3000 (Affymetrix).
Microarray data analyses were performed using Micro-
soft Excel, Partek Genomics Suite 6.5 (Partek Inc., St.
Louis, MO) and Genespring GX11 (Silicon Genetics,
Redwood City, CA). All data were subjected to per chip
and per gene normalization, quantile normalization and
quality control, and a total of 24,805 genes were used
for further analysis. Microarray data were deposited in
the GEO database with the detailed hybridization infor-
mation according to the MIAME guidelines and
assigned the accession number GSE24129 [17]. To ana-
lyze the correlation of microarray data pairs, we used
the Pearson’s correlation coefficient. In addition, we
adopted the non-negative matrix factorization (NMF)
method, which is an unsupervised classification algo-
rithm [18,19]. The NMF method was performed using
the NMF package in the R system. K = 2-5 indicates the
number of subclasses modeled. To identify specific path-
ways that may be involved in the progression of pre-
eclampsia or FGR, we performed standard gene ontol-
o g y( G O )a n a l y s i su s i n gt h eG e n eS p r i n gs o f t w a r e .W e
also performed gene set enrichment analysis (GSEA), a
computational method that determines whether defined
sets of genes show statistically significant, concordant
differences between two biological states [20,21]. For
this analysis we used GSEA v2.06 software from the
Broad Institute [22]. Gene sets were downloaded from
the Molecular Signatures Database (MSigDB) of this
web site. We used the C2 curated catalogue of func-
tional gene sets to select significant gene sets. A false
discovery rate (FDR) of less than 0.25 and P values of
less than 0.001 were considered significant.
Real-time RT-PCR
To validate the microarray data for selected genes, we
performed quantitative real-time RT-PCR (qRT-PCR)
analysis using the Taqman System (Applied Biosystems,
Foster City, CA). The Superscript First-strand Synthesis
Table 1 Clinical parameters of the study groups
Control FGR PE P Value
(n = 8) (n = 8) (n = 8) Control vs FGR Control vs PE FGR vs PE
Maternal age (y) 31.5 ± 6.5
a 31.4 ± 3.7 31.0 ± 4.7 0.96 0.86 0.86
Prepregnancy Body mass index 21.4 ± 2.3 19.9 ± 1.9 21.7 ± 3.7 0.19 0.83 0.26
Gestational age at delivery (wks) 38.1 ± 0.8 37.3 ± 1.0 34.4 ± 1.8 0.08 <0.01 <0.01
Birth weight (g) 2891.5 ± 309.6 1765.4 ± 483.9 1666.6 ± 441.0 <0.01 <0.01 0.68
Birth weight coefficient 1.007 ± 0.120 0.646 ± 0.151 0.778 ± 0.103 <0.01 <0.01 0.06
Placental weight (g) 571.4 ± 151.0 329.4 ± 61.3 341.3 ± 59.4 <0.01 <0.01 0.70
Systolic BP (mmHg) 111.3 ± 11.1 123.3 ± 14.5 160.6 ± 10.0 0.08 <0.01 <0.01
Diastolic BP (mmHg) 66.9 ± 8.7 77.0 ± 11.9 105.3 ± 9.6 0.07 <0.01 <0.01
Proteinuria (%)
b 0 0 100 n.s. <0.01 <0.01
UmA PI
c 0.76 ± 0.10 1.11 ± 0.32 1.12 ± 0.34 0.01 0.01 0.98
a Data are given as the mean ± standard deviation (SD)
b ≥ 5g in a 24 hour collection
c Pulsatility index of the umbilical artery
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dom primers was used to produce single stranded
cDNA templates. A housekeeping gene, ACTB, was used
to normalize for mRNA levels because its expression
levels among the samples were stable. All RT-PCR reac-
tions were performed in triplicate in a final volume of
25 μl. The cycling conditions used for PCR amplification
were 2 min at 50°C, 30 min at 60°C and 1 min at 95°C
for RT, followed by 40 cycles of 15 sec at 95°C and 1
min at 60°C. For qRT-PCR, we increased the number of
samples in addition to the original 24 samples such that
a total of 41 pre-eclampsia, 16 FGR and 45 normoten-
sive pregnancies were analyzed.
Statistical analysis
Statistical comparisons between groups were performed
using the Student’s t test and one-way analysis of var-
iance (ANOVA) and differences were considered to be
significant at P < 0.05.
Results
We compared the global gene expression profiles of
human placentas from pre-eclamptic and unexplained
FGR cases using oligonucleotide microarrays. Eight sam-
ples were used from each of the patient groups and a
normotensive control group. To perform an overview of
the expression profiles of these samples, we first ana-
lyzed the correlation coefficient for the overall microar-
ray data for each sample pair. Comparisons of the
samples from any two normotensive controls showed
good concordance and a high correlation coefficient
(mean correlation coefficient: 0.980; Figure 1A). In con-
trast, a lack of concordance was found between the nor-
motensive and disease samples (control versus pre-
eclampsia, 0.967; control versus FGR, 0.965), indicating
that the expression of numerous genes is altered in the
placenta upon the onset of pre-eclampsia and FGR (Fig-
ure 1A). In the pre-eclamptic samples, most sample
pairing (FGR1-6) also showed a high correlation coeffi-
cient (0.976), whereas less correlation was observed
between FGR samples (0.956), raising a possibility of
heterogeneous pathophysiology for FGR. Notably also, a
subset of FGR samples (FGR 7 and FRG8) showed high
correlation coefficient with the pre-eclampsia samples
(0.977), suggestive of a common etiological background.
Figure 1 Overall gene expression profile analysis of the placentas from pre-eclamptic and normotensive pregnancies with or without
FGR. A. Correlation coefficient of the microarray data between each sample pair. Red indicates 1.0, whereas black indicates less than 0.9. PE, pre-
eclampsia. B. Clustering analysis using the NMF method. K = 2 (upper panel) or K = 3 (lower panel) indicate the number of modeled subclasses.
Red indicates a high, whereas blue indicates a low correlation coefficient. The cophenetic correlation coefficients were measured as follows:
0.9313 (K = 2), 0.8350 (K = 3), 0.7915 (K = 4), and 0.7838 (K = 5).
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eclamptic women delivered newborns with lower birth
weight percentiles (Table 1).
To further analyze the correlations for each sample
pair, we employed the NMF method to classify the sam-
ples based on the overall microarray data. Based on the
cophenetic correlation coefficient (coph) calculated for
each experiment, K = 2 showed the highest value (coph
= 0.9313), indicating that NMF class assignment for K =
2 was the most robust. In addition, whereas all of the
normotensive controls were classified as Group 2, most
of the pre-eclampsia samples were classified as Group 1.
A subset of the FGR samples was also classified as
Group 1, suggesting a common pathophysiology with
pre-eclampsia for these cases (Figure 1B).
To identify differentially expressed genes in a statisti-
cally significant manner, we performed ANOVA and
fold-change analysis of the data obtained from each
sample group. The gene list obtained from a class com-
parison between the normotensive control and pre-
eclamptic pregnancies (P < 0.05) was filtered to identify
candidates for which the expression levels differed by at
least 1.5-fold between the two groups. We thereby iden-
tified a total of 245 genes. Similar analysis between the
control pregnancy and FGR groups identified a total of
252 genes, including 62 genes in common with the gene
set for pre-eclampsia (Figure 2A). As expected, INHBA,
INHA and FLRG (FSTL3) were found in the pre-eclamp-
sia gene set only, consistent with their previously
described association with this disease [23,24]. Our cur-
rent data were also mainly consistent with our earlier
findings [16]. However, many genes that had been
reported previously to be upregulated in pre-eclampsia,
such as LEP, CGB, CRH and PAPP-A2 [25,26], were
identified in the gene sets for both pre-eclampsia and
unexplained FGR in our present analyses (Tables 2, 3
Figure 2 Comparative gene expression profiling of patients with severe pre-eclampsia, unexplained FGR, and normotensive control
pregnancies (n = 8 in each group). A. Venn diagram of the genes found to be differentially expressed between pre-eclamptic and
normotensive control subjects as well as between FGR patients and controls. B. The differential expression profile of representative genes. Upper
panel, genes differentially expressed in pre-eclampsia; middle panel, FGR; lower panel, in both pre-eclampsia and FGR. Each column represents a
single subject and each row indicates a single gene. Gene names are indicated on the left side. The red color indicates up-regulation and blue
depicts down-regulation relative to the controls.
Nishizawa et al. Reproductive Biology and Endocrinology 2011, 9:107
http://www.rbej.com/content/9/1/107
Page 5 of 12and 4, Figure 2B, Additional file 1, Table S1). Interest-
ingly, FLT1 and ENG, which are likely to be associated
with the maternal symptoms of pre-eclampsia [6,7],
were also found to be significantly up-regulated in both
pre-eclampsia and unexplained FGR in our current
study. Our present data thus also support the hypothesis
that pre-eclampsia and a subset of unexplained FGR
share a common background etiology.
To then investigate the differences between the bio-
logical processes underlying the development of pre-
eclampsia and unexplained FGR, we first performed
standard GO analyses, which did not reveal any speci-
fic biological processes or molecular functions for
these disorders (Additional file 2, Tables S2 and Addi-
tional file 3, Tables S3). Next, we performed GSEA
analysis to identify any gene sets that show significant
differences for each sample group. The only significant
functional gene set found for unexplained FGR was
“Insulin_Adip_Insens_dn” (Table 5). This indicates that
the genes downregulated by insulin play a prominent
role in FGR and hence that the insulin pathway is spe-
cifically activated in unexplained cases of this disorder
[27]. For the pre-eclampsia group, “Kannan_P53_up”,
consisting of TP53-responsive genes, was the only gene
set found to be enriched (Table 6) [28]. Among the 36
genes in this set, five genes (BCL6, ENG, SCGB2A2,
ADFP and NHLH2) were considered to contribute to
the enrichment score (core enrichment), and the
expression levels were significantly different in the
genes BCL6, ENG, ADFP, BAX and PMAIP1 (Figure
3A). Clustering analysis using the total set of 36 genes
assigned the pre-eclamptic samples and a subset of the
unexplained FGR specimens to the same tree branches
(Figure 3B).
Table 2 The most highly differentially expressed genes in
the pre-eclampsia samples
Gene name Genbank Fold-Change P Value
Up-regulated genes
FSTL3 NM_005860 3.30 0.0028
SERPINA3 NM_001085 2.90 0.0137
INHBA NM_002192 2.42 0.0004
EBI3 NM_005755 2.08 0.0016
TREM1 NM_018643 2.05 0.0062
BCL6 NM_001706 2.02 0.0024
RNU2-1 NR_002716 1.99 0.0013
SLCO2A1 NM_005630 1.91 0.0053
INHA NM_002191 1.90 0.0019
SNORD115-5 NR_003297 1.87 0.0481
PVRL4 NM_030916 1.80 0.0030
GBA NM_000157 1.80 0.0022
DERL3 NM_198440 1.78 <0.0001
KRT19 NM_002276 1.75 0.0071
LOC728220 ENST00000391570 1.75 0.0369
Down-regulated genes
CLDN1 NM_021101 2.23 0.0051
LOC100129345 XM_001724751 2.18 0.0165
FAM164A AF151820 2.15 0.0003
C20orf69 BC118988 2.00 0.0011
ZNF117 NM_015852 2.00 0.0044
ANKRD20B NR_003366 1.98 0.0230
PART1 AF163475 1.95 <0.0001
DKFZP434B2016 AL137655 1.94 0.0138
C7 NM_000587 1.74 0.0224
PDGFD NM_025208 1.74 0.0070
LEPREL1 NM_018192 1.74 <0.0001
HSD17B1 NM_000413 1.74 <0.0001
ABCG2 NM_004827 1.68 0.0069
OR51B5 NM_001005567 1.67 0.0003
CFH NM_000186 1.66 0.0372
Table 3 The most highly differentially expressed genes in
the FGR samples
Gene name Genbank Fold-Change P Value
Up-regulated genes
CXCL9 NM_002416 2.44 0.0373
KRTAP26-1 NM_203405 1.91 0.0400
LOX NM_002317 1.88 0.0020
CXCL13 NM_006419 1.74 0.0177
FPR3 NM_002030 1.73 0.0365
FLJ11827 XR_040865 1.71 0.0113
IFNG NM_000619 1.70 0.0195
RGS1 NM_002922 1.69 0.0092
THBS1 NM_003246 1.90 0.0013
GZMK NM_002104 1.67 0.0206
CYR61 NM_001554 1.65 0.0231
MSR1 NM_002445 1.63 0.0384
IFI44L NM_006820 1.63 0.0347
TIMP1 NM_003254 1.62 0.0263
C1QB NM_000491 1.60 0.0440
Down-regulated genes
OR4F16 NM_001005277 1.85 0.0192
RPS6KA6 NM_014496 1.82 0.0029
PCDH11Y NM_032971 1.69 0.0211
GABRE U92285 1.64 0.0276
MGC35361 AK298753 1.64 0.0076
KIAA1467 NM_020853 1.63 0.0078
HIST1H2BK NM_080593 1.61 0.0189
GABRA4 NM_000809 1.58 0.0018
LOC441233 AK128010 1.56 0.0321
PGAP1 NM_024989 1.55 0.0004
LRP2 NM_004525 1.55 0.0076
AGL NM_000028 1.53 0.0069
CCDC125 NM_176816 1.53 0.0021
HYAL4 NM_012269 1.53 0.0102
C9orf131 AK090398 1.52 0.0034
Nishizawa et al. Reproductive Biology and Endocrinology 2011, 9:107
http://www.rbej.com/content/9/1/107
Page 6 of 12To confirm the activation of the TP53 pathway in pre-
eclampsia, qRT-PCR for TP53-related genes was per-
formed using an increased number of samples (41 pre-
eclampsia, 16 FGR and 45 normotensive pregnancy spe-
cimens) to validate our microarray results. The expres-
sion of TP53 itself did not change among the three
Table 4 The most highly differentially expressed genes common to pre-eclampsia and FGR









LEP NM_000230 10.94 <0.0001 3.56 0.0066
CGB NM_000737 4.72 0.0011 2.50 0.0391
CGB5 NM_033043 4.71 0.0012 2.46 0.0436
CGB1 NM_033377 4.61 0.0010 2.38 0.0430
CGB7 NM_033142 4.43 0.0012 2.37 0.0445
CGB2 NM_033378 4.37 0.0007 2.37 0.0329
HTRA4 NM_153692 4.00 0.0002 1.93 0.0471
CRH NM_000756 3.66 0.0008 2.36 0.0191
PAPPA2 NM_020318 2.55 0.0001 1.72 0.0125
NTRK2 NM_006180 2.50 <0.0001 1.58 0.0111
CP NM_000096 2.44 0.0445 2.44 0.0446
FLT1 NM_002019 2.39 0.0001 1.51 0.0347
HTRA1 NM_002775 2.20 0.0015 1.67 0.0276
QPCT NM_012413 2.12 0.0008 1.60 0.0240
ENG NM_000118 2.03 0.0003 1.56 0.0143
Down-regulated genes
ACOXL NM_001105516 2.39 <0.0001 1.92 0.0003
GSTA3 NM_000847 2.09 0.0014 1.60 0.0318
HIST1H1T NM_005323 2.06 0.0003 2.03 0.0004
FAM26D NM_153036 2.05 0.0009 1.83 0.0040
SNORD116 AF241255 1.98 0.0203 2.07 0.0140
CATSPERB NM_024764 1.98 0.0001 1.66 0.0023
WNT2 NM_003391 1.97 0.0023 1.58 0.0301
MUC15 NM_145650 1.89 0.0024 1.52 0.0371
SH3TC2 NM_024577 1.89 0.0012 1.63 0.0092
C12orf39 BC004336 1.85 0.0044 1.55 0.0366
TMEM136 NM_174926 1.84 <0.0001 1.61 0.0007
ZNF554 NM_001102651 1.76 0.0005 1.71 0.0009
APLN NM_017413 1.76 0.0007 1.65 0.0020
NAALADL2 NM_207015 1.73 0.0039 1.71 0.0045
ZNF429 NM_001001415 1.70 0.0027 1.56 0.0096
Table 6 Gene sets enriched in pre-eclampsia






Nominal P values <1% are listed.
Table 5 Gene sets enriched in FGR











Nominal P values <1% are listed.
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ever, a significant up-regulation of the downstream
genes BCL6, ENG, ADFP, APLP1, SURF1 and BAX was
confirmed in pre-eclampsia. Among these genes, the
apoptosis-related genes BCL6, ENG and BAX appeared
to be upregulated also in unexplained FGR, but at lower
levels compared with the pre-eclamptic placentas.
Among the other genes related to apoptosis, FASLG
and P53AIP1 w e r ea l s of o u n dt ob eu p - r e g u l a t e di n
pre-eclampsia (Table 7). However, the genes encoding
caspases were not up-regulated, suggesting that apopto-
sis itself is not executed in pre-eclampsia.
Discussion
To date, a large body of evidence has accumulated with
regards to the global expression profiles of the pre-
eclamptic placenta, and several important genes have
been identified via this strategy [16,29,30]. On the other
hand, although there are a comparable number of
reports showing microarray analysis for the FGR pla-
centa, these investigations have not been as effective in
identifying potentially causative genes for this disease.
Previous studies have documented that genes involved
in hypoxia or metabolism-related genes are common to
the group of differentially expressed genes in the FGR
placenta [31-34]. However, these findings may require
careful interpretation, since the expression of these
genes is often affected by sampling site bias [35,36]. In
addition, although the question of whether pre-eclamp-
sia and FGR share a common etiology is not a long-
standing issue, there have been few comparative expres-
sion profiles undertaken for these disorders, and the
results are not consistent [37,38].
In our current study, comparative analysis of the glo-
bal expression profiles of pre-eclampsia and FGR indi-
cate a common pathophysiology. This is based on our
findings that 1) pre-eclampsia and a subset of FGR sam-
ples show a high correlation coefficient for their overall
microarray data and are clustered into the same cate-
gory, and 2) most of the genes known to be up-regu-
lated in pre-eclampsia were found to be up-regulated in
FGR. A possible interpretation might be that pre-
eclampsia and a subset of FGR are in fact the same dis-
order with the same etiology, and that the apparent dif-
ferences depend on the degree of severity. Alternatively,
it is possible that these two disorders are related
Figure 3 GSEA for differentially expressed genes from pre-eclamptic placental tissue. Red indicates up-regulation and blue indicates
down-regulation. A. Heat map for the gene set, “Kannan_P53_up” which consisted of 36 genes (identified on the right). B. Hierarchical
clustering of all subjects using the Kannan_P53_up gene set. Each column represents a single subject and each row a single gene. The height of
the branches reflects the correlation coefficient.
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Page 8 of 12conditions with the same etiology and differing only by
the presence of maternal hypertension.
It was important to then address whether the presence
or absence of maternal symptoms determines the phe-
notypic difference between pre-eclampsia and unex-
plained FGR. Although standard GO analyses did not
reveal specific biological processes or molecular func-
t i o n s ,t h ed a t af r o mG S E Aa n a l y s e ss h o wt h a tTP53
downstream genes are more highly activated in pre-
eclampsia than in FGR. As TP53 itself is not up-regu-
lated at the mRNA level, this activation is likely due to
stabilization of the p53 protein, which has a known
short half-life [39]. Up-regulated genes in pre-eclampsia
also included BAX and BCL6, which are known to regu-
late apoptosis [40,41]. A prevailing hypothesis is that
trophoblast hypoxia due to abnormal spiral arteries trig-
gers apoptosis leading to the onset of pre-eclampsia
[42]. The TP53 pathway may contribute to this process.
The current literature does not support the contribution
of TP53 to pre-eclampsia but a considerable body of evi-
dence indicates that the apoptosis of trophoblasts itself
is increased in the pre-eclamptic placenta [43-45].
Our present data indicate that most of the genes
known to be up-regulated in the placenta in pre-
eclampsia are also up-regulated in unexplained FGR pla-
centas. These genes include FLT1 and ENG,w h i c h
encode soluble proteins that are detected in the mater-
nal circulation and serve as anti-angiogenic factors [6,7].
These data are consistent with previously published
findings [46-49]. Although conflicting data have also
been reported [50,51], it might be possible that the FGR
samples in these reports might be derived from late-
onset cases that are fundamentally different at the mole-
cular level [52]. High levels of these circulating factors
Figure 4 qRT-PCR analysis of TP53-related genes. These data were compared for normotensive control pregnancies (open bars; n = 45), FGR
(dotted bars; n = 16) and pre-eclampsia (grey bars; n = 41). Each bar represents the mean value and each vertical line indicates the standard
deviation. *P < 0.05, ANOVA test. The up-regulation of ADFP was described also in our previous study [16].
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Page 9 of 12are likely to induce maternal systemic endothelial dys-
function. There is little doubt also that the apoptosis of
trophoblasts is associated with cell turnover in the pla-
cental villi [53]. This apoptotic process halts at an early
stage, and dissolution and fusion of the plasma mem-
brane leads to generation of syncytiotrophoblasts, with
accompanying microparticles shedding to the maternal
circulation [54,55]. Excess shedding, possibly due to a
hypoxia-induced increased turnover of syncytiotropho-
blasts, is often observed in the pre-eclamptic placenta
and manifests as syncytial knots [56]. It is possible
therefore that an up-regulation of the TP53 pathway
induces the deportation of microparticles, including
high levels of anti-angiogenic factors, and that this
might facilitate maternal systemic symptoms in pre-
eclampsia [57,58].
Several reports have now indicated that placentas from
FGR pregnancies without pre-eclampsia also manifest
increased apoptosis or the up-regulation of TP53
[59-61]. However, the levels of the apoptotic response in
FGR appear to be less severe than in pre-eclampsia [62].
In this context, our present data suggest that a subset of
unexplained FGR might possibly be pre-eclampsia with
mild maternal symptoms that do not fit the currently
accepted disease criteria. Our qRT-PCR data showing
that TP53-downstream genes are highly up-regulated in
pre-eclampsia and in some cases of unexplained FGR
lend moderate support to this hypothesis. Hence, in
spite of the preliminary nature of the study due to the
small sample size, these data warrant further
investigation.
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